Ocera Therapeutics Overview

  • Year Founded
  • 1998

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 19

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $117M

  • Investors
  • 1

Ocera Therapeutics General Information

Description

Developer of novel therapeutics designed to treat acute and chronic liver diseases. The company's novel therapeutics portfolio consists of OCR-002, an ammonia scavenger used in both intravenous (IV) and oral formulations for the treatment of hyperammonemia and STOP-HE, enabling physicians to receive biopharmaceuticals that helps in resolving neurocognitive symptoms of acute HE.

Contact Information

Formerly Known As
Tranzyme
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 555 Twin Dolphin Drive
  • Suite 615
  • Redwood City, CA 94065
  • United States
+1 (650)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Corporate Office
  • 555 Twin Dolphin Drive
  • Suite 615
  • Redwood City, CA 94065
  • United States
+1 (650)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ocera Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Merger/Acquisition 01-Dec-2017 $117M Completed Generating Revenue
11. Debt - General 30-Jul-2015 Completed Generating Revenue
10. 2PO 15-Jul-2014 Completed Generating Revenue
9. PIPE 06-Nov-2013 Completed Generating Revenue
8. PIPE 16-Jul-2013 Completed Generating Revenue
7. Reverse Merger 15-Jul-2013 Completed Generating Revenue
6. Debt - General 05-Apr-2012 Completed Generating Revenue
5. Later Stage VC (Series C) 20-Feb-2008 Completed Startup
4. Early Stage VC (Series B) 10-Jul-2006 $12M $35.3M Completed Startup
3. Early Stage VC (Series A) 17-Jan-2006 $14.7M $23.3M Completed Startup
To view Ocera Therapeutics’s complete valuation and funding history, request access »

Ocera Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C
Series B
Series A 14,720,000 $0.001000 8% $1 $1 1x $1 27.63%
To view Ocera Therapeutics’s complete cap table history, request access »

Ocera Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of novel therapeutics designed to treat acute and chronic liver diseases. The company's novel therapeutics por
Biotechnology
Redwood City, CA
19 As of 2016

Skokie, IL
 

New York, NY
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Ocera Therapeutics Competitors (97)

One of Ocera Therapeutics’s 97 competitors is Cour, a Venture Capital-Backed company based in Skokie, IL.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Cour Venture Capital-Backed Skokie, IL
Xalud Therapeutics Venture Capital-Backed New York, NY
HepaRegenix Venture Capital-Backed Tubingen, Germany
AnTolRx Formerly VC-backed Cambridge, MA
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
You’re viewing 5 of 97 competitors. Get the full list »

Ocera Therapeutics Patents

Ocera Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021277201-A1 Uses of ornithine phenylacetate for treating hyperammonemia Inactive 22-May-2020
CA-3182891-A1 Uses of ornithine phenylacetate for treating hyperammonemia Pending 22-May-2020
EP-4153162-A1 Uses of ornithine phenylacetate for treating hyperammonemia Pending 22-May-2020
EP-4153162-A4 Uses of ornithine phenylacetate for treating hyperammonemia Pending 22-May-2020
WO-2021236522-A1 Uses of ornithine phenylacetate for treating hyperammonemia Inactive 22-May-2020 A61P1/16
To view Ocera Therapeutics’s complete patent history, request access »

Ocera Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ocera Therapeutics Former Investors (23)

Investor Name Investor Type Holding Investor Since Participating Rounds
AgeChem Financial Venture Capital Minority
BDC Capital Growth/Expansion Minority
Bonaventure Capital Venture Capital Minority
CDIB BioScience Venture Management Venture Capital Minority
Cross Creek Advisors Venture Capital Minority
You’re viewing 5 of 23 investors. Get the full list »

Ocera Therapeutics Acquisitions (1)

Ocera Therapeutics’s most recent deal was a Merger/Acquisition with Tranzyme. The deal was made on 15-Jul-2013.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Tranzyme 15-Jul-2013 Merger/Acquisition Pharmaceuticals
To view Ocera Therapeutics’s complete acquisitions history, request access »

Ocera Therapeutics FAQs

  • When was Ocera Therapeutics founded?

    Ocera Therapeutics was founded in 1998.

  • Where is Ocera Therapeutics headquartered?

    Ocera Therapeutics is headquartered in Redwood City, CA.

  • What is the size of Ocera Therapeutics?

    Ocera Therapeutics has 19 total employees.

  • What industry is Ocera Therapeutics in?

    Ocera Therapeutics’s primary industry is Biotechnology.

  • Is Ocera Therapeutics a private or public company?

    Ocera Therapeutics is a Private company.

  • What is the current valuation of Ocera Therapeutics?

    The current valuation of Ocera Therapeutics is .

  • What is Ocera Therapeutics’s current revenue?

    The current revenue for Ocera Therapeutics is .

  • How much funding has Ocera Therapeutics raised over time?

    Ocera Therapeutics has raised $166M.

  • Who are Ocera Therapeutics’s investors?

    AgeChem Financial, BDC Capital, Bonaventure Capital, CDIB BioScience Venture Management, and Cross Creek Advisors are 5 of 23 investors who have invested in Ocera Therapeutics.

  • Who are Ocera Therapeutics’s competitors?

    Cour, Xalud Therapeutics, HepaRegenix, AnTolRx, and Inovio Pharmaceuticals are some of the 97 competitors of Ocera Therapeutics.

  • When was Ocera Therapeutics acquired?

    Ocera Therapeutics was acquired on 01-Dec-2017.

  • Who acquired Ocera Therapeutics?

    Ocera Therapeutics was acquired by Mallinckrodt Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process